Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
MENLO PARK, Calif., January 20, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed the closing of our previously announced definitive agreement with Akeso Inc. (HKEX Code: 9926.HK, "Akeso") to in-license its breakthrough bispecific antibody, ivonescimab. Ivonescimab, known as AK112 in China and Australia, and as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential first-in-class bispecific antibody comb
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Summit...
MENLO PARK, Calif., January 05, 2023--Summit Therapeutics will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 09, 2023, at 3:45 PM PST.
Shares of Summit Therapeutics (NASDAQ: SMMT) were up 34.3% for the week as of late Friday morning, according to data from S&P Global Market Intelligence. The stock was up as much as 52% at one point this week, closing out last week at $3.67, then soaring to as high as $5.54 on Thursday. For the year, the clinical-stage biopharmaceutical stock is up a whopping 84.7%.
If you want to know who really controls Summit Therapeutics Inc. ( NASDAQ:SMMT ), then you'll have to look at the...
Shares of Summit Therapeutics (NASDAQ: SMMT) were skyrocketing 371.8% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. This huge gain came after the company announced on Tuesday that it's licensing bispecific antibody ivonescimab from Chinese drugmaker Akeso. Akeso will retain the rights to market the therapy throughout the rest of the world, including China.
Akeso Inc announced a collaboration and license agreement with Summit Therapeutics Inc (NASDAQ: SMMT) to out-license its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for development and commercialization in the U.S., Canada, Europe, and Japan. In addition, the company will co-brand the product in the license territories. Currently, Akeso is conducting a phase 3 trial of ivonescimab monotherapy versus pembrolizumab monotherapy as the first-line treatment for NSCLC patients wit
$500 Million Upfront Payment to Activate the Partnership for IvonescimabMenlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”), to in-license its breakthrough bispecific antibody, ivonescimab. Akeso is a pioneer and source originator in developing innovative antibodies. The agree
Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. “Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. “As we intend to expand our p
Summit Therapeutics ( NASDAQ:SMMT ) Third Quarter 2022 Results Key Financial Results Net loss: US$21.4m (loss widened...